2012年8月11日星期六
Universal Detector Measures Major Biomolecule Classes
Dual vector for inhibition of human immunodeficiency virus
Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses.
Related Articles |
Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses.
Drugs. 1975;10(5-6):351-6
Authors: Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS
PMID: 1204506 [PubMed - indexed for MEDLINE]
Pupil Dilation May Reveal Sexuality
Group Health Experience Shows How Practice And Research Can Inform Each Other
2012年8月10日星期五
Bosutinib Buyer Beware
[Cutaneous side-effects of nonsteroidal anti-inflammatory drugs (NSAID)].
Related Articles |
[Cutaneous side-effects of nonsteroidal anti-inflammatory drugs (NSAID)].
Z Rheumatol. 1995 Nov-Dec;54(6):405-12
Authors: Gebhardt M, Wollina U
Abstract
NSAID are able to induce cutaneous side-effects by both systematical and topical application. Nearly all kinds of exanthema are possible by any type of these drugs. However, particular substances are more likely to induce certain drug eruptions; aspirin and indometacine may induce urticarial reactions, whereas piroxicam can lead to phototoxic or photoallergic dermatitis. Contact dermatitis induced by topical NSAID is still rare but increasing. Ketoprofen and bufexamac were major contact allergens based on the number of reports, but local differences among different countries were observed. The diagnosis of drug reactions, especially in systemic drugs, remains a problem because reliable in vitro methods are not yet in use and skin test procedures do not work in most cases. Therefore, the case history is still the most useful tool in evaluating anamnestic allergic events. Prospective studies of drug compatibility as well as an improvement of side-effect reports are necessary to assess specific risks for several drugs.
PMID: 8578891 [PubMed - indexed for MEDLINE]
Therapeutic inhibitor of vascular smooth muscle cells
[Bufexamac-induced pigmented purpuric eruption].
Related Articles |
[Bufexamac-induced pigmented purpuric eruption].
Hautarzt. 2009 May;60(5):424-7
Authors: Waltermann K, Marsch WCh, Kreft B
Abstract
We report on a case of a bufexamac-induced allergic contact dermatitis with hematogenous dissemination presenting with the clinical and histological picture of a pigmented purpuric eruption. To our knowledge this is the first report on a bufexamac-induced pigmented purpuric dermatosis. It represents a further example of the clinical variety of cutaneous side-effects caused by bufexamac.
PMID: 19093092 [PubMed - indexed for MEDLINE]
2012年8月9日星期四
[Current contact allergens].
Related Articles |
[Current contact allergens].
Z Hautkr. 1987 Dec 1;62(23):1631-4, 1637-8
Authors: Frosch PJ
Abstract
We present the patch test results of 2,623 patients treated at the Department of Dermatology, University of Heidelberg, from July, 1984 to June, 1986. One test at least was positive in 680 patients (25.9%). 257 allergens produced a total of 1,450 positive reactions. (average: 2.1 per patient). 9.7% of the allergens caused 64.4% of the positive reactions. The 5 most frequent allergens were nickel sulfate, balsam of Peru, formaldehyde, neomycin sulfate, and cobalt sulfate. Mixed fragrances and Kathon CG were among the 20 most frequent allergens though only tested during half of the study period. Glyceril monothioglycolate was the leading allergen with hairdressers. Other allergens clinically relevant were rubber gloves, bufexamac, bronopol, and propolis.
PMID: 2964130 [PubMed - indexed for MEDLINE]
War On Weeds
Pharmaceutical composition, methods for treating and uses thereof
[Role of chemotherapy in castration-resistant prostate cancer: are there new approaches?].
Related Articles |
[Role of chemotherapy in castration-resistant prostate cancer: are there new approaches?].
Urologe A. 2012 Jan;51(1):39-43
Authors: De Santis M, Bachner M
Abstract
Chemotherapy options for the treatment of metastatic castration-resistant prostate cancer (CRPC) have been very limited for many decades. Until 2004, only mitoxantrone was approved, providing palliation, but no survival benefit. With the introduction of docetaxel, the landscape of chemotherapy for CRPC changed substantially. Prednisone and three-weekly docetaxel showed an overall survival (OS) benefit compared to mitoxantrone plus prednisone, in addition to a significant improvement of quality of life and pain reduction. Further strategies to treat CRPC with chemotherapy include reinduction with docetaxel in responding patients and the use of cabazitaxel, a novel semi-synthetic microtubule inhibitor, in the docetaxel-refractory population. This review article is meant to guide physicians through the optimal use of chemotherapy in CRPC patients in daily clinical practice.
PMID: 22258375 [PubMed - indexed for MEDLINE]
2012年8月8日星期三
The topical anti-inflammatory effects of piroxicam in rodents.
Related Articles |
The topical anti-inflammatory effects of piroxicam in rodents.
Agents Actions. 1980 Jun;10(3):246-51
Authors: Larson DL, Lombardino JG
Abstract
Piroxicam is a structurally novel, long-acting anti-inflammatory drug with potent activity following oral administration in animal models of inflammation and in human inflammatory diseases. The present studies, performed in rats, demostrate that topically applied piroxicam is a potent inhibitor of inflammation induced by either carrageenin or complete Freund's adjuvant. Comparable potencies (ED50 approximately 1--5 mg/kg) were obtained for topically and orally administered piroxicam in these models of inflammation. The potency of topical piroxicam exceeds that of topically applied bufexamac or phenylbutazone in the rat adjuvant arthritis model.
PMID: 7405751 [PubMed - indexed for MEDLINE]
Building A Jellyfish
Despite Law, Critically Ill Uninsured Americans Still At Risk Of Being Turned Away From Hospitals
Biomarkers Help Pinpoint Mechanisms, Predict Outcomes In Depression
Kinase inhibitors
2012年8月7日星期二
[A common and insidious side-effect: allergic contact dermatitis caused by bufexamac used in the treatment of dermatitis. Results from the Information Network of Departments of Dermatology (IDVK)].
Related Articles |
[A common and insidious side-effect: allergic contact dermatitis caused by bufexamac used in the treatment of dermatitis. Results from the Information Network of Departments of Dermatology (IDVK)].
Dtsch Med Wochenschr. 2005 Dec 16;130(50):2881-6
Authors: Schnuch A, Gefeller O, Uter W
Abstract
BACKGROUND AND OBJECTIVE: Bufexamac is a non-steroidal, anti-inflammatory drug used in the topical treatment of atopic dermatitis, stasis dermatitis and perianal eczema. The substance is known to cause severe allergic contact dermatitis (ACD) as an adverse effect (AE), which may be indistinguishable from the eczema which is to be treated. Hence the diagnosis of this AE is often considerably delayed. In order to estimate the quantitative importance of ACD to bufexamac, data of the Information Network of (German) Departments of Dermatology (IVDK) from July 1999 to December 2004 were analysed.
PATIENTS AND METHODS: During the study period, 39,392 unselected patients from 40 German departments of the IVDK were patch tested with bufexamac (5 % pet). The results of the reading after 72 hours were analysed. The dichotomized patch test result was further assessed for possible risk factors from the patients' history and clinical diagnosis by Poisson regression analysis.
RESULTS: In 560 of 39,392 patients contact allergy to bufexamac was diagnosed, i. e. 1.4 % (95 % confidence interval: 1.3 - 1.5), standardized for sex and age. The Poisson regression analysis revealed a significantly increased risk associated with the following factors: multiple sensitization, perianal eczema, underlying atopic dermatitis, leg dermatitis, female gender and residence in areas of Germany other than Eastern Germany. The latter observation can be explained by low prescription rates in Eastern Germany.
CONCLUSION: Bufexamac is an important allergen. Extrapolating the frequency of 1.4 % in our data to the whole German population by the CE-DUR approach yields an estimate of about 6000 cases per year. In view of the high frequency of sensitization, the pitfalls in diagnosis, the severity of the course of disease and the lack of efficacy of this drug, the risk to benefit ratio is obviously critical.
PMID: 16342011 [PubMed - indexed for MEDLINE]
Bufexamac HDAC Inhibitors Bufexamac 2438-72-4 Bufexamac 1353882-38-8
Single Amino Acid Forms Fibrils
Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of...
Lactam compounds useful as protein kinase inhibitors
Thiazolopyrimidinone derivatives as pi3 kinase inhibitors
This invention relates to novel compounds of formula (I):...
2012年8月6日星期一
Medical Staff Often Miss Alcohol Problems If Patients Are Not Intoxicated
Oligonucleotides inhibiting cellular migration
Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of...